Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorMin Su

About this trial

Nociception is the encoding and processing of noxious stimulation and is considered an objective indicator for monitoring pain. Currently, a new clinically-applied medical-engineering integrated monitoring device for noxious stimulation response has emerged. Its fundamental principle is based on the monitoring of electroencephalographic (EEG) activity, incorporating two monitoring parameters: the quantitative consciousness (qCON) index and the quantitative nociceptive (qNOX) index. However, in the context of sedation for gastrointestinal endoscopy, how the dynamic changes of the quantitative consciousness index (qCON) and the quantitative nociception index (qNOX) reflect the depth of sedation and nociceptive response remains unclear. Safe and effective sedation monitoring includes both direct visual monitoring and physiological monitoring, that is, monitoring the patient's hemodynamics and depth of sedation. This study utilizes qCON and qNOX monitoring to assess the sedation and analgesic states of patients undergoing painless gastroenterological endoscopy. By combining visual assessment (cough reflex, respiratory depression, and limb movement) with clinical physiological monitoring (vital signs monitoring and pulse oximetry), the aim is to explore the optimal sedation range for gastrointestinal endoscopy under sedation, providing new anesthesia monitoring tools for clinical use.

Eligibility criteria

Qualifiers

Aged 18-60 years old;

American Society of Anesthesiologists (ASA) Class I-III;

Body mass index (BMI): 18-30 kg/m²;

Individuals scheduled for elective gastroscopy and colonoscopy examinations;

Disqualifiers

Pregnant or breastfeeding women;

Individuals with allergies to sedatives/anesthetic drugs or other severe anesthetic risks;

Patients with chronic preoperative pain or a history of substance abuse;

Individuals with severe neurological diseases, such as stroke, hemiplegia, seizures, epilepsy, etc.;

Trial design

Treatments tested in this trial

  • EEG monitoring

Treatment groups

220 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Min Su

Lead sponsor

First Affiliated Hospital of Chongqing Medical University

Sponsor institution